Botanical species · safety record

Anamirta paniculata

The EFSA Compendium of Botanicals holds 7 constituent measurements for Anamirta paniculata. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Anamirta paniculata Colebr.

7Constituent measurements
0Safety records
7Cited sources
3Licensed products (Canada)

Also recorded as

Synonyms are carried from the source compendium. A species may be traded and studied under more than one name, which is exactly how a safety record gets lost.

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 3 licensed products naming Anamirta paniculata as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Source material stated

  • Tincture of the seeds, coarsely powdered

What the records describe

Constituents measured

  • Picrotoxin2
  • Sesquiterpene lactones2
  • Isoquinoline alkaloids1
  • Oxypalmatine1
  • Triterpene saponins1

Plant parts

  • Stem3
  • stalk3
  • Fruit unspecified2
  • Seed2

Preparations

  • Solvent extraction4

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

SubstancePlant partPreparationConcentrationAnalytical methodSource
Isoquinoline alkaloidsStem / stalkSolvent extractionNuclear Magnetic Resonance (NMR)Resolve DOI
Sesquiterpene lactonesSeedSolvent extractionNuclear Magnetic Resonance (NMR)Resolve DOI
OxypalmatineStem / stalkSolvent extraction5e-04 PercentStandard Chromatographic tests (paper- thin layer- and column chromatography)No resolvable identifier
PicrotoxinFruit unspecifiedSolvent extraction1.4 PercentUnspecifiedNo resolvable identifier
PicrotoxinSeed1.2 PercentNo resolvable identifier
Sesquiterpene lactonesFruit unspecifiedNo resolvable identifier
Triterpene saponinsStem / stalkNo resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

  1. Jayasinghe, U. L. B., Wannigama, G. P., Balasubramaniam, S., Nasir, Habib., Atta-ur-Rahman. Benzylisoquinoline alkaloids from Anamirta cocculus and Diploclisia glaucescens. Journal of the national science council of sri lanka, 1992, vol. 20, no. 2, p. 187-90.
  2. VERPOORTE, R., SIWON, J., TIEKEN, MEM., SVENDSEN, AB. STUDIES ON INDONESIAN MEDICINAL-PLANTS .5. THE ALKALOIDS OF ANAMIRTA-COCCULUS . Journal of natural products, 1981, vol. 44, no. 2, p. 221-224. DOI
  3. Clark, E. P. Preparation of picrotoxin. Journal of the american chemical society, 1935, vol. 57, p. 1111.
  4. Amma, K. Pankajakshi. Chemical examination of plant products possessing insecticidal properties. Bulletin of the research institute, university of kerala, trivandrum, series a: physical sciences, 1954, vol. 3(Ser. A), p. 129-32.
  5. Jayasinghe, U. L. B., Wannigama, G. P., Fujimoto, Y. Chemistry and bioactivity of saponins from some Sri Lankan plants. Proceedings of the phytochemical society of europe, 2000, vol. 45(Saponins in Food, Feedstuffs and Medicinal Plants), p. 113-119.
  6. Agarwal, SK., Singh, SS., Verma, S., Kumar, S. Two picrotoxin derivatives from Anamirta cocculus. Phytochemistry, 1999, vol. 50, no. 8, p. 1365-1368. DOI
  7. Pradhan, P., Mamdapur, V. R., Sipahimalani, A. T. Methyl picrotoxate, a minor component of berries of plant Anamrita cocculus and its stereochemistry by high resolution NMR spectroscopy. Indian journal of chemistry, section b: organic chemistry including medicinal chemistry, 1990, vol. 29B, no. 7, p. 676-7.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue